Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) finished Thursday with an addition of $0.04 to close at $0.21, an upside of 22.94 percent. An average of 5,182,320 shares of common stock have been traded in the last five days. There was a fall of -$0.0159 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 25,228,980 shares traded, while the 50-day average volume stands at 13,195,908.
KPRX stock has increased by 54.13% in the last month. The company shares reached their 1-month lowest point of $0.1220 on 08/23/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.12 and a high of $2.34 in 52 weeks. It has reached a new high 1 time so far this year and lost -86.16% or -$1.3010 in price. In spite of this, the price is down -91.07% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Kiora Pharmaceuticals Inc. (KPRX) stock’s beta is 0.22. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.31.
The quick ratio of Kiora Pharmaceuticals Inc. for the three months ended June 29 was 1.50, and the current ratio was 1.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $14.24 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Kiora Pharmaceuticals Inc.’s return on assets was -74.60%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$2.4 million in the quarter, while revenues of -$3.57 million were shrunk -2.92%. The analyst consensus anticipated Kiora Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.2 per share, but it turned out to be -$0.18, a 10.00% surprise. For the quarter, EBITDA amounted to -$2.39 million. Shareholders own equity worth $36.76 million.
From a technical analysis perspective, let’s take a brief look at Kiora Pharmaceuticals Inc. (KPRX) price momentum. RSI 9-day as of the close on 22 September was 52.00%, suggesting the stock is Neutral, with historical volatility in this time frame at 203.08%.
As of today, KPRX’s price is $0.2058 -7.07% or -$0.0159 from its 5-day moving average. KPRX is currently trading +58.21% higher than its 20-day SMA and -60.57% lower than its 100-day SMA. However, the stock’s current price level is -46.22% below the SMA50 and -83.54% below the SMA200.
The stochastic %K and %D were 16.23% and 23.78%, respectively, and the average true range (ATR) was 0.0369. With the 14-day stochastic at 38.54% and the average true range at 0.0358, the RSI (14) stands at 51.31%. The stock has reached -0.0258 on the 9-day MACD Oscillator while the 14-day reading was at -0.0204.
The consensus rating for Kiora Pharmaceuticals Inc. (KPRX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell KPRX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is KPRX’s price target for the next 12 months?
Analysts predict a range of price targets between $2.50 and $6.50, with a median target of $4.50. Taking a look at these predictions, the average price target given by analysts for Kiora Pharmaceuticals Inc. (KPRX) stock is $4.50.